SG Americas Securities LLC Takes Position in ClearPoint Neuro, Inc. $CLPT

SG Americas Securities LLC acquired a new stake in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) in the first quarter, HoldingsChannel reports. The institutional investor acquired 372,356 shares of the company’s stock, valued at approximately $3,388,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd bought a new stake in ClearPoint Neuro during the 4th quarter worth approximately $25,000. BNP Paribas Financial Markets boosted its position in shares of ClearPoint Neuro by 2,435.2% in the second quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock worth $27,000 after purchasing an additional 2,143 shares during the period. Legal & General Group Plc purchased a new stake in shares of ClearPoint Neuro in the second quarter worth $35,000. Huntington National Bank bought a new stake in shares of ClearPoint Neuro during the 3rd quarter valued at $44,000. Finally, Russell Investments Group Ltd. raised its position in shares of ClearPoint Neuro by 1,079.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company’s stock valued at $51,000 after purchasing an additional 2,158 shares during the period. 30.08% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at ClearPoint Neuro

In related news, CEO Joseph Burnett sold 1,843 shares of the business’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $17.94, for a total value of $33,063.42. Following the sale, the chief executive officer directly owned 191,388 shares in the company, valued at approximately $3,433,500.72. The trade was a 0.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Timothy T. Richards sold 5,415 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $12.17, for a total value of $65,900.55. Following the transaction, the director directly owned 87,198 shares of the company’s stock, valued at approximately $1,061,199.66. The trade was a 5.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 88,349 shares of company stock valued at $1,408,518. 6.94% of the stock is owned by company insiders.

ClearPoint Neuro Stock Performance

Shares of NASDAQ CLPT opened at $17.84 on Wednesday. The company has a debt-to-equity ratio of 2.63, a quick ratio of 4.88 and a current ratio of 5.79. The company has a market cap of $535.02 million, a P/E ratio of -17.66 and a beta of 1.31. The firm’s fifty day moving average is $13.28 and its two-hundred day moving average is $12.74. ClearPoint Neuro, Inc. has a 52-week low of $8.27 and a 52-week high of $30.10.

ClearPoint Neuro (NASDAQ:CLPT) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.04). ClearPoint Neuro had a negative return on equity of 140.96% and a negative net margin of 71.57%.The company had revenue of $12.13 million during the quarter, compared to analysts’ expectations of $11.97 million. As a group, analysts anticipate that ClearPoint Neuro, Inc. will post -1.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CLPT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Monday, April 20th. B. Riley Financial raised their price target on ClearPoint Neuro from $20.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Finally, Stifel Nicolaus set a $16.00 price objective on ClearPoint Neuro in a research report on Tuesday, June 9th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, ClearPoint Neuro currently has a consensus rating of “Hold” and an average target price of $23.00.

ClearPoint Neuro Profile

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.